TN8 fundamentals

Key facts

Market capitalization‪189.85 B‬EUR
Founded1960
Employees (FY)‪125 K‬
CEOMarc N. Casper
About

Thermo Fisher Scientific, Inc. engages in the provision of analytical instruments, equipment, reagents and consumables, software, and services for research, analysis, discovery, and diagnostics. It operates through the following segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services. The Life Sciences Solutions segment is composed of a portfolio of reagents, instruments, and consumables used in biological and medical research, discovery and production of new drugs and vaccines, as well as diagnosis of infection and disease. The Analytical Instruments segment offers instruments, consumables, software, and services that are used for a range of applications in the laboratory, on the production line, and in the field. The Specialty Diagnostics segment provides diagnostic test kits, reagents, culture media, instruments, and associated products used to increase the speed and accuracy of diagnoses. The Laboratory Products and Services segment is involved in providing everything needed for the laboratory, including a combination of self-manufactured and sourced products for customers in research, academic, government, industrial, and healthcare settings. The company was founded on October 11, 1960 and is headquartered in Waltham, MA.

Ownership
‪‪377.26 M‬‬
Free Float shares
‪‪376.60 M‬‬ (99.82%)
Closely held shares
‪‪665.11 K‬‬ (0.18%)
Free Float shares
‪‪376.60 M‬‬ (99.82%)
Closely held shares
‪‪665.11 K‬‬ (0.18%)
Capital structure
Market cap
‪‪189.85 B‬‬
Debt
‪‪31.66 B‬‬
Minority interest
‪‪84.04 M‬‬
Cash & equivalents
‪‪5.39 B‬‬
Enterprise value
‪‪216.20 B‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪189.85 B‬‬
Price to earning ratio (P/E)
31.98x
Price to sales ratio (P/S)
4.72x
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
31.98x
Price to sales ratio (P/S)
4.72x
Valuation ratios
‪0.00‬
‪1.50‬
‪3.00‬
‪4.50‬
‪6.00‬
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪0.00‬
‪10.00‬
‪20.00‬
‪30.00‬
‪40.00‬
P/E
P/S

Growth and Profitability

Company’s recent performance and margins

Performance
‪10.0%‬
‪11.6%‬
‪13.2%‬
‪14.8%‬
‪16.4%‬
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪0.00‬
‪‪3.00 B‬‬
‪‪6.00 B‬‬
‪‪9.00 B‬‬
‪‪12.00 B‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪0.00‬
‪‪3.00 B‬‬
‪‪6.00 B‬‬
‪‪9.00 B‬‬
‪‪12.00 B‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪0.00‬
‪‪3.00 B‬‬
‪‪6.00 B‬‬
‪‪9.00 B‬‬
‪‪12.00 B‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business
Period: 2024
Laboratory Products and Biopharma Services
Life Sciences Solutions
Analytical Instruments
Specialty Diagnostics
By country
Period: 2024
United States
Europe
Asia-Pacific
Other Regions
North America

Estimates

Revenue and Earnings forecasts and estimates accuracy

Revenue
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪0.00‬
‪‪3.00 B‬‬
‪‪6.00 B‬‬
‪‪9.00 B‬‬
‪‪12.00 B‬‬
Actual
Estimate
Earnings
Next:Apr 23, 2025
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪0.00‬
‪1.50‬
‪3.00‬
‪4.50‬
‪6.00‬
Actual
Estimate

Dividends

Dividend yield, history and sustainability

Dividend summary
9.44%
Earnings retained
Payout ratio (TTM)
Dividend yield TTM
0.30%
Next payment
0.414
Next ex-date
Mar 14, 2025
Dividend history
‪0.15%‬
‪0.19%‬
‪0.23%‬
‪0.27%‬
‪0.31%‬
2020
2021
2022
2023
2024
‪0.00‬
‪0.40‬
‪0.80‬
‪1.20‬
‪1.60‬
Dividends per share (FY)
Dividend yield (FY) %

Financial health

Financial position and solvency of the company

Debt level and coverage
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪0.00‬
‪‪9.00 B‬‬
‪‪18.00 B‬‬
‪‪27.00 B‬‬
‪‪36.00 B‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
‪0.00‬
‪‪20.00 B‬‬
‪‪40.00 B‬‬
‪‪60.00 B‬‬
‪‪80.00 B‬‬
Assets
Liabilities